Last 1,109 INR
Change Today -6.85 / -0.61%
Volume 3.2K
ASTR On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca pharma india ltd (ASTR) Snapshot

Open
1,104
Previous Close
1,115
Day High
1,126
Day Low
1,104
52 Week High
03/4/14 - 1,286
52 Week Low
08/6/13 - 634.00
Market Cap
27.7B
Average Volume 10 Days
5.1K
EPS TTM
-0.20
Shares Outstanding
25.0M
EX-Date
07/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTRAZENECA PHARMA INDIA LTD (ASTR)

Related News

No related news articles were found.

astrazeneca pharma india ltd (ASTR) Related Businessweek News

No Related Businessweek News Found

astrazeneca pharma india ltd (ASTR) Details

AstraZeneca Pharma India Limited engages in the manufacture, distribution, and marketing of pharmaceutical products in India and internationally. It operates in three segments: Healthcare, Clinical Trial Services, and Co-promotional Services. The company primarily provides products in the areas of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation healthcare. Its products include Betaloc, Seloken XL, Imdur, Crestor, Seloram, Vigocil, Vigocil M, Nitract SR, Valfect,Olways, Olways H, Olways AM for cardiovascular diseases; and Onglyza, Kombiglyze XR, and Byetta for diabetes. The company also offers Mit’s Linctus Codeinae Co, Mit’s Linctus DX, Bricarex, Bricarex A, Bricacef, Bricacef PED, Bricanyl Syrup, and Symbicort for respiratory diseases; Prostodin, Cerviprime, and Partocin for maternal healthcare; Arimidex, Nolvadex, Iressa, Zoladex, Casodex, and Faslodex for oncology; and Meronem, Vancocin CP, Enclere, and Remergin for infections. In addition, it provides Xylocaine, Sensorcaine, Diprivan, and Naropin for neuroscience; and Neksium tablets and injections for gastrointestinal diseases. The company was incorporated in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Founded in 1979

astrazeneca pharma india ltd (ASTR) Top Compensated Officers

Vice President of Operations
Total Annual Compensation: 3.9M
Whole-Time Director and Member of Share Trans...
Total Annual Compensation: 2.7M
Compensation as of Fiscal Year 2013.

astrazeneca pharma india ltd (ASTR) Key Developments

AstraZeneca Pharma India Limited Reports Audited Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014

AstraZeneca Pharma India Limited reported audited earnings results for the fourth quarter and full year ended March 31, 2014. For the quarter, the company reported total income from operations (net) of INR 1,141.522 million compared to INR 949.165 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 178.742 million compared to INR 192.474 million a year ago. Loss from ordinary activities before tax was INR 25.688 million compared to INR 185.753 million a year ago. Net loss for the period was INR 25.688 million or INR 1.03 per basic and diluted share, compared to INR 185.753 million or INR 7.43 per basic and diluted share, a year ago. For the year to date, the company reported total income from operations (net) of INR 4,739.710 million compared to INR 3,904.21 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 230.975 million compared to INR 807.33 million a year ago. Loss from ordinary activities after tax was INR 5.089 million compared to INR 895.324 million a year ago. Net loss for the period was INR 5.089 million or INR 0.20 per basic and diluted share, compared to INR 895.324 million or INR 35.81 per basic and diluted share, a year ago.

AstraZeneca Pharma India Limited to Report Q4, 2014 Results on May 30, 2014

AstraZeneca Pharma India Limited announced that they will report Q4, 2014 results on May 30, 2014

AstraZeneca Pharma India Limited, Board Meeting, May 30, 2014

AstraZeneca Pharma India Limited, Board Meeting, May 30, 2014. Agenda: To consider the audited financial results of the company for the fourth quarter and year ended March 31, 2014 and may also consider recommendation of dividend for the financial year ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTR:IN 1,108.55 INR -6.85

ASTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASTR.
View Industry Companies
 

Industry Analysis

ASTR

Industry Average

Valuation ASTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 16.2x
Price/Cash Flow 290.3x
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PHARMA INDIA LTD, please visit www.astrazenecaindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.